Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Post-hoc subgroup analysis from PACIFIC: durvalumab after CRT in unresectable stage III EGFRm NSCLC

Standard of care for patients with unresectable stage III non small-cell lung cancer is based on the results from the Phase III PACIFIC (NCT02125461) trial where consolidation durvalumab following chemoradiotherapy improved overall survival (OS) and progression-free survival (PFS). In this interview, Jarushka Naidoo, MD, John Hopkins University, Baltimore, MD, presents findings from a post hoc exploratory efficacy and safety analysis from 35 patients with EGFR-mutant NSCLC enrolled in the PACIFIC trial. The PFS and OS were similar with durvalumab when compared to placebo in this EGFR-mutant population, highlighting the unknown benefit of immune checkpoint blockade in this population. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.